Treatment - Page 26 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of adding sipuleucel-T (Provenge) androgen receptor-targeting agents (ARTAs) such as abiraterone acetate (AA; Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC). The data showed that those receiving both sipuleucel-T and ARTAs were more...

Read More

Evaluating the combined daratumumab, lenalidomide and dexamethasone therapy for patients with multiple myeloma, based on frailty levels.

Evaluating the combined daratumumab, lenalidomide and dexamethasone therapy for patients with multiple myeloma, based on frailty levels.

Posted by on Apr 3, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness and safety of using daratumumab (Darzalex) with lenalidomide (Revlimid) and dexamethasone (Decadron)(D-Rd) to lenalidomide and dexamethasone (Rd) treatment in patients with newly diagnosed multiple myeloma (NDMM), based on frailty levels. The data showed that D-Rd was more effective than Rd at improving...

Read More

Can filgotinib affect patient-reported outcomes and health-related quality of life in patients with rheumatoid arthritis?

Can filgotinib affect patient-reported outcomes and health-related quality of life in patients with rheumatoid arthritis?

Posted by on Apr 3, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to...

Read More

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Apr 3, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of mosunetuzumab (RG7828) for the treatment of patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that mosunetuzumab resulted in long-lasting complete responses with manageable side effects for these patients. Some background NHL is cancer that...

Read More

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Posted by on Apr 3, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICI) plus chemotherapy versus chemotherapy alone for the treatment of patients with triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was more effective than chemotherapy alone and was associated with a higher rate of side...

Read More

Can high-frequency spinal cord stimulation provide relief to patients with painful diabetic nerve disease?

Can high-frequency spinal cord stimulation provide relief to patients with painful diabetic nerve disease?

Posted by on Mar 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the long-term impact of 10-kHz spinal cord stimulation (SCS) in patients with painful diabetic neuropathy (PDN; nerve disease) and refractory symptoms. The data supported the use of 10-kHz SCS for important, durable pain relief over 12 months in these patients. Some background Diabetic sensorimotor peripheral...

Read More

Investigating the effectiveness and safety of combining low-intensity extracorporeal shock wave therapy with tadalafil and L-arginine for the treatment of erectile dysfunction.

Investigating the effectiveness and safety of combining low-intensity extracorporeal shock wave therapy with tadalafil and L-arginine for the treatment of erectile dysfunction.

Posted by on Mar 20, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with tadalafil (Cialis) and L-arginine for the treatment of patients with mild and moderate erectile dysfunction (ED). The data showed that daily therapy with tadalafil and L-arginine increased the...

Read More

Evaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.

Evaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.

Posted by on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of blinatumomab (Blincyto) for the treatment of children with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The data showed that blinatumomab was safe and effective for these patients. Some background B-ALL is a type of cancer in which the body makes...

Read More

Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel

Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel

Posted by on Mar 15, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the effect of idecabtagene vicleucel (ABECMA; ide-cel) treatment on health-related quality of life (HR-QoL) in patients with relapsed or refractory (r/r) multiple myeloma (MM).   This study concluded that this treatment improves HR-QoL for these patients.   Some...

Read More

Evaluating the effectiveness and safety of ropinirole for the treatment of Parkinson’s disease.

Evaluating the effectiveness and safety of ropinirole for the treatment of Parkinson’s disease.

Posted by on Feb 27, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ropinirole (Requip) for the treatment of patients with Parkinson’s disease (PD). The data showed that ropinirole was effective in improving motor function and daily living of patients with PD but was associated with an increase in side effects. Some background Parkinson's...

Read More

Evaluating the effectiveness of immunotherapy in advanced lung cancer with and without brain metastases.

Evaluating the effectiveness of immunotherapy in advanced lung cancer with and without brain metastases.

Posted by on Feb 27, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of immunotherapy in advanced lung cancer (LC) patients with and without brain metastases (BMs). The data showed that immunotherapy significantly improved overall survival in LC patients with and without BMs. Some background In 20-40% of patients with advanced LC, the cancer spreads from the lung to...

Read More

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Posted by on Feb 25, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of trilaciclib (Cosela) given before gemcitabine (Gemzar) plus capecitabine (Xeloda) (GC) chemotherapy regimen in patients with metastatic triple-negative breast cancer (mTNBC). The data showed that trilaciclib given before GC chemotherapy regimen was effective and significantly improved overall...

Read More